Design and evaluation of chalconeimine derivatives as α-amylase inhibitors

Abstract

Alpha-amylase is a known target for type II diabetes. Therefore, it is of interest to design a-amylase inhibitors based on hydrazone scaffold. The structure of these hybrids was confirmed by spectroscopic analysis (IR, H-1-and C-13 NMR). All the compounds have potential inhibitory properties as shown by in vitro alpha-amylase inhibition activity. The compound 5-((1Z,3Z)-3-(benzo[d][1,3]dioxol-5-yl)-3-((2-chloropyridin-3-yl)imino)prop-1-en-1-yl)-2-(difluoromethoxy)phenol(4a) in 100 mu g/mL concentration showed a high inhibition of 85.23%. In vitro alpha-amylase inhibition was further supported by docking studies of compound against the active site of pig pancreatic alpha-amylase (PDB ID: 3L2M). Docking studies revealed that the bonding interactions found between the compound and human pancreatic a-amylase are similar to those responsible for a-amylase inhibition by acarbose.